aspirin , sulfinpyrazone and the combination of aspirin/dipyridamole , which inhibit some aspects of platelet function , have been evaluated in large-scale clinical trials in secondary prevention of myocardial infarction .
C0004057
aspirin
C0027051
myocardial infarction